Image Source: Unsplash
 

The Chart of the Day belongs to the biotechnology company Dyne Therapeutics (DYN). I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 5/15 the stock gained 26.65%.

(Click on image to enlarge)

DYN Price vs Daily Moving Averages

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
 

Barchart Technical Indicators:

• 100% technical buy signals
• 159.64+ Weighted Alpha
• 238.58% gain in the last year
• Trend Seeker buy signal
• Above its 20, 50 and 100 day moving averages
• 6 new highs and up 20.27% in the last month
• Relative Strength Index 64.18%
• Technical support level at $32.50
• Recently traded at $37.21 with 50 day moving average of $30.94
   

Fundamental Factors:

• Market Cap $2.94 billion
• Earnings estimated to grow 23.80% this year

Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:

• Wall Street analysts issued 6 strong buy and 4 buy recommendations
• Value Line rates the stock its above average rating of 2
• CFRAs MarketScope has a sell rating
• MorningStar gives the stock an average 3 star rating with a Fair Value of $50 that's a 32% discount
• 1,270 investors monitor the stock on Seeking Alpha

More By This Author:

Chart Of The Day: National HealthCare - Skilled Nursing Facilities
Chart Of The Day: Arista Networks - 10 Year Gain Of 2,115%
Chart Of The Day: Microsoft - Everyone Loves Mr Softy